monoclonal antibody CD20-Fred Hutchinson Cancer Center-B-cell malignancy

The drug entry "monoclonal antibody CD20-Fred Hutchinson Cancer Center-B-cell malignancy" refers to a specific anti-CD20 monoclonal antibody, historically identified as clone 1F5, developed and utilized by the Fred Hutchinson Cancer Center (FHCC) for the treatment of B-cell malignancies. In clinical research settings, such as the Phase I/II trial NCT00003875, this antibody is used for the *ex vivo* depletion of malignant B-cells from peripheral blood stem cell (PBSC) components prior to autologous transplantation. By targeting the CD20 antigen, which is expressed on the surface of mature B-lymphocytes and most B-cell lymphomas, the antibody facilitates the purging of tumor cells from the graft while allowing for the enrichment of CD34+ hematopoietic stem cells. This procedure is intended to reduce the risk of disease recurrence caused by the re-infusion of cancerous cells during hematopoietic stem cell transplantation.

Other names

anti-CD20 monoclonal antibodyanti-CD-20 monoclonal antibodyanti-CD 20 monoclonal antibodyCD20 antibodyCD-20 antibodyCD 20 antibodymonoclonal antibody CD20